Jaypirca (Pirtobrutinib) Patent Expiration, LOE Window & CMS Spending

Jaypirca (Pirtobrutinib) by Eli Lilly: FDA Orange Book core substance LOE 2036-12-16 (last listed 2041-09-14), 0 AB generics, $207.0M 2024 CMS Part D & Medicaid spend, and $21,000 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorEli Lilly
FDA Application & PathwayN216059 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2036-12-16
Last Listed Patent or Exclusivity Date2041-09-14
Orange Book Patents (*PED Extensions)7 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$207.0M
2024 Medicare Part D Spend$200.6M
2024 Medicaid Spend$6.5M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($21,000 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Eli Lilly and Company across sibling Meru public-data platforms.